Category Archives: TRIPS flexibilities

Speech of Dr. Tedros (WHO Director-General) – l Symposium on Sustainable Development Goals: Innovative technologies to promote healthy lives and well-being

WHO Headquarters, Geneva 26 February 2018 My brother Roberto, my brother Francis, Distinguished participants, colleagues, ladies and gentlemen, Good morning, and welcome to WHO. It’s great to have you here. As you know, universal health coverage is one of the … Continue reading

Posted in Patent, Trade Agreements, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Big pharma against CL move but WHO agrees

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO). WHO advocates universal health coverage and that means … Continue reading

Posted in Compulsory Licensing, Uncategorized | Leave a comment

Extreme TB: Centre yet to push for cheaper versions of two crucial drugs

By Vidya Krishnan, The Hindu | March 4, 2018 Compulsory licence for 2 drugs may be needed, but Centre isn’t ready yet Advanced patented medicines used to treat Drug Resistant Tuberculosis (DR-TB) are available to only about 1,000 patients out of the … Continue reading

Posted in Access to Medecines, Compulsory Licensing, Tuberculosis (TB), Uncategorized | Leave a comment

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

PhRMA is angered by Colombia’s move to cut prices for hepatitis C drugs

By Ed Silverman, StatNews In the latest battle between drug makers and the Colombian government,  an industry trade group has asked the Colombian health minister to scrap a move that is designed to unilaterally lower the prices of hepatitis C drugs or, eventually, issue compulsory licenses. … Continue reading

Posted in Compulsory Licensing, Drug prices, Hepatitis C, Uncategorized | Leave a comment

UACT statement regarding Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs

January 8, 2018 New Delhi Source: U Act UACT applauds the Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. … Continue reading

Posted in Compulsory Licensing, Hepatitis C | Leave a comment

Justice Prabha Sridevan on Life, Laughter and IP

By Shamnad Basheer, Spicy IP | January 4, 2018 As promised in our new year post on the relativity of “newness” (and the impending death of the patent system), we bring to you our freshly minted SpicyIP Interview series. And who better … Continue reading

Posted in Compulsory Licensing, Patent, Uncategorized | Leave a comment